Response from the Original Author: Author's Reply to Walter and Guyatt

Senn SJ Individual therapy: New dawn or false dawn. Drug Inf J. 2001;35:1479–1494.

Guyatt GH Juniper EF Walter SD Griffith LE Goldstein RS Interpreting treatment effects in randomised trials [see comments]. Br Med J. 1998;316:690–693.

Senn SJ Statistical Issues in Drug Development. Chichester, United Kingdom: John Wiley; 1997.

Senn SJ Applying results of randomised trials to patients. N of 1 trials are needed [letter; comment]. Br Med J. 1998;317:537–538.

Shumaker RC Metzler CM The phenytoin trial is a case study of “individual bioequivalence.” Drug Inf J. 1998;32:1063–1072.

Anderson S Hauck WW Consideration of individual bioequivalence. J Pharmacokinetics Biopharmaceutics. 1990;18:259–273.

Senn SJ Statistical quality in analysing clinical trials. Good Clin Practice J. 2000;7:22–26.

Senn SJ Authorship of drug industry trials. Pharmaceutical Stat. 2002;1:5–7.

Guyatt G Juniper EF Goldstein BJ Author's reply. Br Med J. 1998;317:537.

Senn SJ Cross-over Trials in Clinical Research. Chichester, United Kingdom: John Wiley; 2002.

Walter SD Number needed to treat (NNT): Estimation of a measure of clinical benefit. Stat Med. 2001;20:3947–3962.

Juniper EF Johnston PR Borkhoff CM Guyatt GH Boulet LP Haukioja A. Quality of life in asthma clinical trials: Comparison of salmeterol and salbutamol. Am J Respir Crit Care Med. 1995;151:66–70.

Juniper EF Guyatt GH Ferrie PJ Griffith LE Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147:832–838.

Horwitz RI Singer BH Makuch RW Viscoli CM Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation [see comments]. J Clin Epidemiol. 1996;49:395–400.